Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATOS NASDAQ:BHST NYSEMKT:IGC NASDAQ:MCRB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Genetics$0.82-1.3%$0.85$0.55▼$1.66$107.73M0.921.34 million shs684,773 shsBHSTBioHarvest Sciences$7.69+1.2%$7.00$4.66▼$7.99$124.83M0.659,359 shs816 shsIGCIGC Pharma$0.34+5.2%$0.33$0.25▼$0.48$29.48M1.45913,992 shs214,616 shsMCRBSeres Therapeutics$13.99-1.9%$10.33$6.53▼$26.40$124.52M2.89147,021 shs47,064 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Genetics-1.32%-2.01%-1.68%-3.79%-39.04%BHSTBioHarvest Sciences+1.18%+1.45%+12.76%+17.76%+768,999,900.00%IGCIGC Pharma-3.92%-4.46%+11.73%+12.83%+34,299,900.00%MCRBSeres Therapeutics-1.89%-3.72%+28.82%+45.28%-47.80%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATOSAtossa Genetics2.6047 of 5 stars3.74.00.00.02.01.70.0BHSTBioHarvest SciencesN/AN/AN/AN/AN/AN/AN/AN/AIGCIGC Pharma1.387 of 5 stars3.50.00.00.00.61.70.0MCRBSeres Therapeutics2.9283 of 5 stars2.91.00.04.61.70.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATOSAtossa Genetics 3.33Buy$6.17649.29% UpsideBHSTBioHarvest Sciences 3.00Buy$13.6777.72% UpsideIGCIGC Pharma 3.00Buy$3.881,029.74% UpsideMCRBSeres Therapeutics 1.75Reduce$73.67426.57% UpsideCurrent Analyst Ratings BreakdownLatest IGC, BHST, ATOS, and MCRB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/6/2025ATOSAtossa GeneticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.25 ➝ $7.506/5/2025ATOSAtossa GeneticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$4.005/8/2025MCRBSeres TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$1.25 ➝ $6.005/5/2025BHSTBioHarvest SciencesCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$15.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATOSAtossa GeneticsN/AN/AN/AN/A$0.57 per shareN/ABHSTBioHarvest Sciences$27.70M4.56N/AN/A$0.08 per share96.13IGCIGC Pharma$1.27M21.50N/AN/A$0.08 per share4.29MCRBSeres Therapeutics$126.32M0.97N/AN/A$1.61 per share8.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATOSAtossa Genetics-$25.50M-$0.21N/AN/AN/AN/A-33.90%-31.53%8/11/2025 (Estimated)BHSTBioHarvest Sciences-$12.91M-$0.50N/AN/AN/A-31.30%-307.04%-33.21%8/14/2025 (Estimated)IGCIGC Pharma-$13M-$0.08N/AN/AN/A-714.16%-122.44%-88.40%N/AMCRBSeres Therapeutics$140K-$4.60N/AN/AN/AN/A-41,084.76%-55.87%8/6/2025 (Estimated)Latest IGC, BHST, ATOS, and MCRB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025ATOSAtossa Genetics-$0.06N/AN/AN/AN/AN/A8/6/2025Q2 2025MCRBSeres Therapeutics-$2.72N/AN/AN/AN/AN/A5/15/2025Q1 2025BHSTBioHarvest Sciences-$0.15-$0.13+$0.02-$0.13$8.93 million$7.64 million5/13/2025Q1 2025ATOSAtossa Genetics-$0.06-$0.05+$0.01-$0.05N/AN/A5/7/2025Q1 2025MCRBSeres Therapeutics-$0.67-$2.24-$1.57$3.75$10.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATOSAtossa GeneticsN/AN/AN/AN/AN/ABHSTBioHarvest SciencesN/AN/AN/AN/AN/AIGCIGC PharmaN/AN/AN/AN/AN/AMCRBSeres TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATOSAtossa GeneticsN/A12.6712.67BHSTBioHarvest SciencesN/A0.510.30IGCIGC Pharma0.021.150.98MCRBSeres TherapeuticsN/A2.112.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATOSAtossa Genetics12.74%BHSTBioHarvest SciencesN/AIGCIGC Pharma3.87%MCRBSeres Therapeutics59.34%Insider OwnershipCompanyInsider OwnershipATOSAtossa Genetics7.60%BHSTBioHarvest SciencesN/AIGCIGC Pharma31.48%MCRBSeres Therapeutics4.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATOSAtossa Genetics8129.17 million119.35 millionOptionableBHSTBioHarvest SciencesN/A16.43 millionN/AN/AIGCIGC Pharma6179.69 million54.60 millionN/AMCRBSeres Therapeutics3308.73 million8.32 millionOptionableIGC, BHST, ATOS, and MCRB HeadlinesRecent News About These CompaniesSeres Therapeutics (MCRB) Expected to Announce Earnings on WednesdayJuly 31 at 10:31 AM | marketbeat.comSeres Therapeutics: Speculative Gem Backed By SER‑155 FDA BreakthroughJuly 31 at 3:53 AM | seekingalpha.comSeres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025July 22, 2025 | globenewswire.comSBI Securities Co. Ltd. Purchases 48,013 Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB)July 20, 2025 | marketbeat.comSeres Therapeutics (NASDAQ:MCRB) Shares Cross Above Fifty Day Moving Average - What's Next?July 5, 2025 | marketbeat.comSeres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual MeetingMay 27, 2025 | globenewswire.comSeres Therapeutics (MCRB) Upgraded to Buy: What Does It Mean for the Stock?May 23, 2025 | zacks.comWall Street Analysts Believe Seres Therapeutics (MCRB) Could Rally 713.09%: Here's is How to TradeMay 16, 2025 | zacks.comSeres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2025 Earnings Call TranscriptMay 9, 2025 | insidermonkey.comChardan Capital Downgrades Seres Therapeutics (MCRB)May 9, 2025 | msn.comSeres Therapeutics, Inc. (MCRB) Q1 2025 Earnings Call TranscriptMay 7, 2025 | seekingalpha.comSeres Therapeutics reports Q1 EPS $3.75, consensus $1.97May 7, 2025 | msn.comSeres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdatesMay 7, 2025 | globenewswire.comSeres Therapeutics Q1 2025 Earnings PreviewMay 6, 2025 | msn.comWhy Seres Therapeutics, Inc.’s (MCRB) Stock Is Down 5.09%May 6, 2025 | aaii.comASeres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune DiseasesApril 29, 2025 | globenewswire.comPetri Dish: Boston Scientific CFO retires; Biotech undergoes 1-for-20 reverse stock splitApril 24, 2025 | bizjournals.comSeres Therapeutics trading resumesApril 24, 2025 | markets.businessinsider.comSeres Therapeutics trading halted, volatility trading pauseApril 24, 2025 | markets.businessinsider.comSeres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025April 23, 2025 | globenewswire.comSeres Therapeutics trading halted, news pendingApril 22, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military Spend3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonAmerica Wants Drone Dominance: Are These Stocks Ready to Soar?By Chris Markoch | July 20, 2025View America Wants Drone Dominance: Are These Stocks Ready to Soar?3 Drone Stocks Take Flight on Hegesth's Bold Memo: Who and WhyBy Leo Miller | July 16, 2025View 3 Drone Stocks Take Flight on Hegesth's Bold Memo: Who and WhyKratos Defense Is Changing Warfare—Here’s What’s Driving ItBy Jeffrey Neal Johnson | July 24, 2025View Kratos Defense Is Changing Warfare—Here’s What’s Driving ItIGC, BHST, ATOS, and MCRB Company DescriptionsAtossa Genetics NASDAQ:ATOS$0.82 -0.01 (-1.32%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.83 +0.01 (+1.22%) As of 08/1/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.BioHarvest Sciences NASDAQ:BHST$7.69 +0.09 (+1.18%) As of 08/1/2025 03:43 PM EasternBioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.IGC Pharma NYSEMKT:IGC$0.34 +0.02 (+5.18%) Closing price 08/1/2025 03:58 PM EasternExtended Trading$0.34 0.00 (-0.58%) As of 08/1/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.Seres Therapeutics NASDAQ:MCRB$13.99 -0.27 (-1.89%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$13.95 -0.04 (-0.29%) As of 08/1/2025 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
